References
- Schrijvers D, Vermorken J B. Phase I studies with bendamustine: an update. Semin Oncol 2002; 29: 15–18
- Rummel M J, Mitrou P S, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol 2002; 29: 27–32
- Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002; 29: 4–11
- Chow K U, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou P S, Weidmann E. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86: 485–493
- Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab (BMR) in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299–1306
- Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004; 45: 2445–2449
- Rummel M J, Al-Batran S E, Kim S Z, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
- Herold M, Schulze A, Niederwieser D, Franke A, Fricke H J, Richter P, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105–112
- van der Jagt R H, Cohen P, Cheson B, Tulpule A, Herst J A, Lemieux B, et al. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma. Blood 2006; 108: 766a
- Forero-Torres A, Cohen P, Cheson B D, Robinson K S, La Casce A S, Fayad L, et al. A phase II study of single-agent bendamustine in rituximab-refractory B-cell non-Hodgkin's lymphoma. Ann Oncol 2006; 17(Suppl 9)ix203